Xencor (XNCR) Cash from Financing Activities (2013 - 2026)
Xencor's (XNCR) quarterly Cash from Financing Activities came in at $950000.0 in Q1 2026, down 23.94% year-on-year from $1.2 million in Q1 2025, and down 84.97% on a QoQ basis from $6.3 million in Q4 2025.
Xencor (XNCR) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Cash from Financing Activities data on file, last reported at $950000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 23.94% year-over-year to $950000.0 in Q1 2026; TTM through Mar 2026 was $7.9 million, a 95.97% decrease from a year earlier, with the FY2025 full-year figure at $8.2 million, down 95.82% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $950000.0, down from $6.3 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for XNCR reached as high as $189.9 million in Q3 2024 and fell as low as $356000.0 in Q3 2023.
- Historically, Cash from Financing Activities has averaged $25.1 million across 5 years, with a median of $1.3 million in 2022.
- On a YoY basis, Cash from Financing Activities climbed as much as 53232.58% in 2024 and fell as far as 97.62% in 2024.
- Year by year, Cash from Financing Activities stood at $1.2 million in 2022, then jumped by 15785.57% to $186.0 million in 2023, then tumbled by 97.62% to $4.4 million in 2024, then jumped by 42.65% to $6.3 million in 2025, then tumbled by 84.97% to $950000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $950000.0 in Q1 2026, $6.3 million in Q4 2025, and $662000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | 950,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 950,000.00 |
| Mar 31, 2026 | 950,000.00 |
| Dec 31, 2025 | 6.32 Mn |
| Dec 31, 2025 | 6.32 Mn |
| Jun 30, 2025 | 662,000.00 |
| Jun 30, 2025 | 662,000.00 |
| Mar 31, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Sep 30, 2024 | 189.86 Mn |
| Sep 30, 2024 | 189.86 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 186.02 Mn |
| Dec 31, 2023 | 186.02 Mn |
| Sep 30, 2023 | 356,000.00 |
| Sep 30, 2023 | 356,000.00 |